Permethrin
Brand names: Lyclear (5% cream)
Permethrin is a topical insecticide used for scabies and head lice.
Adult dose
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to the active substance permethrin, to other substances of the pyrethrin group, or to any of the excipients — in such cases treatment should be switched to a chemically different antiscabies agent (§4.3)
Side effects
- Common — paraesthesia and skin burning sensation
- Common — pruritus, erythematous rash, dry skin
- Rare — headache; nausea; excoriation, folliculitis, skin hypopigmentation
- Very rare — contact dermatitis, urticaria
- Dyspnoea in sensitive/allergic patients; in scabies, itching may persist for up to 4 weeks post-treatment (allergic reaction to dead mites, not necessarily treatment failure)
Interactions
- §4.5: 'No interactions are known.'
- Corticosteroids — treatment of eczematous-like reactions with corticosteroids should be withheld prior to treatment with permethrin 5% w/w cream, as there is a risk of exacerbating the scabies infestation by reducing the immune response to the mite (§4.5)
Clinical monograph
How it works
It is a synthetic pyrethroid that disrupts sodium channel function in the parasite's nerve membranes, causing paralysis and death of mites and lice.
Prescribing in practice
- For scabies, treat all close physical and household contacts at the same time, whether or not they have symptoms, to prevent reinfestation.
- For scabies, apply to the whole body including the neck, face where affected in older adults, and under the fingernails and toenails, washing off after the period specified in the SPC and usually repeating the application.
- Persistent itching can continue for several weeks after successful treatment and does not by itself indicate failure or the need to re-treat.
Monitoring
No laboratory monitoring is required; review if itching is worsening rather than gradually settling, or if new burrows or lesions appear after treatment, which may suggest reinfestation or treatment failure.
Counselling the patient
- Treat all close contacts and household members on the same day, even those without symptoms.
- For scabies, apply to the whole body as directed, including under the nails, and reapply after laundering hands if they are washed during the treatment period.
- Itching may last for some weeks after the mites are cleared and usually settles; seek review if it is getting worse or new spots appear.
Evidence & guidelines
First-line topical treatment for scabies (NICE CKS scabies).
Reference: NICE NG225; PHE Scabies Guidance; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD